Daily Endocrinology Research Analysis
Three impactful endocrinology-adjacent studies emerged today: an IPD meta-analysis shows corticosteroid benefit in CAP is concentrated at high CRP levels, supporting biomarker-guided therapy; a 130,030-sample big-data analysis proposes population-, method-, and season-specific reference intervals for 25(OH)D; and mechanistic work links histone crotonylation to autophagy/ferroptosis in diabetic wounds, suggesting new targets.
Summary
Three impactful endocrinology-adjacent studies emerged today: an IPD meta-analysis shows corticosteroid benefit in CAP is concentrated at high CRP levels, supporting biomarker-guided therapy; a 130,030-sample big-data analysis proposes population-, method-, and season-specific reference intervals for 25(OH)D; and mechanistic work links histone crotonylation to autophagy/ferroptosis in diabetic wounds, suggesting new targets.
Research Themes
- Biomarker-guided use of corticosteroids in infection
- Population- and assay-specific reference intervals for vitamin D
- Epigenetic regulation of autophagy and ferroptosis in diabetic wound healing
Selected Articles
1. Predicting benefit from adjuvant therapy with corticosteroids in community-acquired pneumonia: a data-driven analysis of randomised trials.
Across eight RCTs (n=3224), adjunct corticosteroids reduced 30-day mortality in hospitalized CAP (OR 0.72). A pre-registered effect model identified baseline CRP as the key effect modifier: patients with CRP >204 mg/L had substantial mortality reduction (OR ~0.43), while those with CRP ≤204 mg/L derived no benefit.
Impact: Defines a simple, measurable biomarker (CRP) to individualize corticosteroid use in CAP, resolving long-standing uncertainty and enabling precision treatment.
Clinical Implications: For hospitalized CAP, consider adjunct corticosteroids when baseline CRP >204 mg/L; avoid routine use at lower CRP. Incorporate CRP-based algorithms, while monitoring hyperglycemia and secondary infection risks.
Key Findings
- Eight RCTs (n=3224) showed lower 30-day mortality with adjunct corticosteroids versus placebo (OR 0.72, 95% CI 0.56–0.94).
- Effect-model external validation identified CRP as the sole predictor of benefit; CRP >204 mg/L had marked mortality reduction (OR ~0.43), CRP ≤204 mg/L showed no benefit (OR ~0.98).
- Findings were pre-registered and validated on two recent trials, supporting reproducibility and generalizability.
Methodological Strengths
- Individual patient data meta-analysis with intention-to-treat and pre-registered analysis plan
- External validation of a data-driven effect model identifying CRP threshold
Limitations
- Heterogeneity in corticosteroid regimens and dosing across trials
- Adverse events and long-term outcomes were not the primary focus
Future Directions: Prospective trials implementing CRP-guided corticosteroid strategies, including optimal dosing/duration and safety profiling in high-CRP CAP.
BACKGROUND: Despite several randomised controlled trials (RCTs) on the use of adjuvant treatment with corticosteroids in patients with community-acquired pneumonia (CAP), the effect of this intervention on mortality remains controversial. We aimed to evaluate heterogeneity of treatment effect (HTE) of adjuvant treatment with corticosteroids on 30-day mortality in patients with CAP. METHODS: In this individual patient data meta-analysis, we included RCTs published before July 1, 2024, comparing adjuvant treatment with corticosteroids versus placebo in patients hosp
2. Histone lysine crotonylation accelerates ACSL4-mediated ferroptosis of keratinocytes via modulating autophagy in diabetic wound healing.
In diabetic skin and high-glucose keratinocytes, elevated H3K27 crotonylation suppresses autophagic flux, stabilizing ACSL4 and accelerating ferroptosis. Blocking H3K27cr (MB-3) increases SQSTM1 transcription, restores autophagy, reduces ACSL4-driven ferroptosis, and improves wound healing in diabetic rats.
Impact: Reveals a novel epigenetic-autophagy-ferroptosis axis in diabetic wound pathophysiology, identifying actionable nodes (H3K27cr, SQSTM1, ACSL4) for therapy.
Clinical Implications: While preclinical, the data support developing small-molecule modulators of H3K27 crotonylation or ACSL4/autophagy pathways to enhance diabetic wound healing.
Key Findings
- Diabetic skin and high-glucose keratinocytes showed heightened ferroptosis (ACSL4-mediated) and suppressed autophagic flux.
- H3K27 crotonylation was markedly elevated; pharmacologic blockade with MB-3 enhanced SQSTM1 transcription, restored autophagy, and reduced ferroptosis.
- Adenoviral ACSL4 knockdown decreased ferroptosis and improved wound healing in diabetic rats.
Methodological Strengths
- Multi-system validation across in vivo (STZ-diabetic rats) and in vitro (high-glucose keratinocytes) models
- Convergent genetic (ACSL4 knockdown) and pharmacologic (MB-3) perturbations to test causality
Limitations
- Preclinical models; human clinical validation is lacking
- Specificity and translational feasibility of MB-3 and epigenetic targeting require further study
Future Directions: Validate H3K27cr–SQSTM1–ACSL4 axis in human diabetic wounds; develop selective modulators and evaluate efficacy/safety in translational and early-phase clinical studies.
Dysfunction of keratinocytes affects diabetic wound healing, but underlying mechanisms have not been understood. This study examines crotonylation's role in ferroptosis and autophagy in keratinocytes, particularly regarding ACSL4, using STZ-induced diabetic rats and high glucose-exposed keratinocytes to assess these processes. The ACSL4 knockdown was achieved using adenovirus in wounds to examine the impact of ferroptosis modulation on healing diabetic wounds. MB-3 was utilized to block the H3K27
3. Redefining vitamin D status: Establishing population-based indirect reference intervals through big data analysis.
Using refineR on 130,030 real-world 25(OH)D results, the study derived population-, method-, and season-specific reference intervals, revealing wide variability and high deficiency prevalence. Method-specific and department/seasonal effects suggest that fixed universal thresholds may misclassify vitamin D status.
Impact: Provides a scalable, data-driven framework to recalibrate 25(OH)D thresholds, potentially reducing overtesting and oversupplementation while aligning with assay and seasonal realities.
Clinical Implications: Adopt population-, assay-, and season-adjusted reference intervals for 25(OH)D interpretation to avoid misclassification and unnecessary supplementation; harmonize lab reports with method-specific RIs.
Key Findings
- Retrospective analysis of 130,030 25(OH)D results (2018–2022) using VDSP-certified Liaison and Atellica assays.
- Estimated RIs varied by transformation and method (e.g., ~10–59 ng/mL by method), with women showing wider RIs than men.
- Vitamin D deficiency (≤20 ng/mL) occurred in 34.2% and severe deficiency (≤12 ng/mL) in 12.6%; strong seasonal effects were observed.
Methodological Strengths
- Very large real-world dataset with two VDSP-certified immunoassays
- Use of refineR algorithm with transformation sensitivity analyses and verification in healthy subset
Limitations
- Single-center dataset (Barcelona) may limit generalizability
- Indirect RI estimation relies on distributional assumptions; residual assay bias possible
Future Directions: Multi-center harmonization studies across platforms and geographies; prospective evaluation of clinical decision impact when using method-/season-specific RIs.
OBJECTIVES: To establish accurate population-based reference intervals (RIs) for serum 25-hydroxyvitamin D [25(OH)D] using the refineR indirect method and real-world data (RWD), accounting for demographic, methodological, and seasonal factors. METHODS: A retrospective analysis of 130,030 serum 25(OH)D samples collected from 2018 to 2022 at a tertiary hospital in Barcelona was performed. Samples were measured using VDSP-certified Liaison and Atellica immunoassays. The refineR algorithm was employe